Jaime Alberto Mejia

机构：Merck & Co., Inc., Rahway, NJ, USA (United States) · ORCID：0000-0002-1315-6878

发表论文 109 篇 · 总被引 5972 次 · h-index 17

代表论文

A Phase 2 Study of In Situ Oncolytic Virus Therapy and Stereotactic Body Radiation Therapy Followed by Pembrolizumab in Metastatic Non-Small Cell Lung Cancer (2023 · International Journal of Radiation Oncology*Biology*Physics · 被引 19)
Abstract GS01-05: Pembrolizumab + Olaparib vs Pembrolizumab + Chemotherapy After Induction With Pembrolizumab + Chemotherapy for Locally Recurrent Inoperable or Metastatic TNBC: Randomized Open-Label Phase 2 KEYLYNK-009 Study (2024 · Cancer Research · 被引 18)
Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study (2023 · European Journal of Cancer · 被引 17)
Abstract LB1-07: Exploratory Biomarker Analysis of the Phase 3 KEYNOTE-522 Study of Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage TNBC (2025 · Clinical Cancer Research · 被引 13)
Contribution of tumour and immune cells to PD‐L1 expression as a predictive biomarker in metastatic triple‐negative breast cancer: exploratory analysis from KEYNOTE ‐119 (2024 · The Journal of Pathology Clinical Research · 被引 13)
KEYLYNK-009: Pembrolizumab plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer after Clinical Benefit from First-Line Pembrolizumab plus Chemotherapy (2025 · Clinical Cancer Research · 被引 5)